Search

Your search keyword '"Voloshin, Sergey"' showing total 498 results

Search Constraints

Start Over You searched for: Author "Voloshin, Sergey" Remove constraint Author: "Voloshin, Sergey"
498 results on '"Voloshin, Sergey"'

Search Results

1. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

2. Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

7. CML-395 Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update

8. CML-155 Prognostic Markers of the Effectiveness of Tyrosine Kinase Inhibitors in Third-Line Therapy of Chronic Phase Chronic Myeloid Leukemia Patients: Data From a Multicenter Study

9. CLL-106 First Prospective Data on Minimal Residual Disease Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-Line Treatment of CLL in Older Adult or Unfit Patients: The GLOW Study

20. P1692: UNMET NEEDS IN PATIENTS WITH “LOW RISK” POLYCYTHEMIA VERA (PV): SYMPTOM BURDEN AND QUALITY OF LIFE

21. Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study

22. Measurement of the low-energy antitriton inelastic cross section

23. Long-term outcomes of third-line therapy with tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: A real-life experience

24. Impact of Minimal Residual Disease on Progression-Free Survival Outcomes after Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study

25. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial

26. Accessing the strong interaction between $\Lambda$ baryons and charged kaons with the femtoscopy technique at the LHC

27. First measurement of the $|t|$-dependence of incoherent J/$\psi$ photonuclear production

28. Higher-order correlations between different moments of two flow amplitudes in Pb$-$Pb collisions at $\sqrt{s_{\rm NN}}=5.02$ TeV

29. Data-driven precision determination of the material budget in ALICE

30. Measurements of inclusive J/$\psi$ production at midrapidity and forward rapidity in Pb$-$Pb collisions at $\sqrt{s_{\mathrm{NN}}}$ = 5.02 TeV

31. Measurement of inclusive J/$\psi$ pair production cross section in pp collisions at $\sqrt{s} = 13$ TeV

32. Inclusive and multiplicity dependent production of electrons from heavy-flavour hadron decays in pp and p$-$Pb collisions

33. Measurements of inclusive J/$\psi$ production at midrapidity and forward rapidity in Pb$-$Pb collisions at $\sqrt{s_{\rm NN}} = 5.02$ TeV

34. Study of the p$-$p$-$K$^+$ and p$-$p$-$K$^-$ dynamics using the femtoscopy technique

35. Jet-like correlations with respect to K$^{0}_{\rm S}$ and $\Lambda$ ($\bar{\Lambda}$) in pp and Pb-Pb collisions at $\mathbf{\it\sqrt{s_\mathrm{NN}}}$ = 5.02 TeV

36. Constraining the \({\overline{\textrm{K}}}{\textrm{N}}\) coupled channel dynamics using femtoscopic correlations at the LHC

37. Measurements of the groomed jet radius and momentum splitting fraction with the soft drop and dynamical grooming algorithms in pp collisions at $ \sqrt{s} $ = 5.02 TeV

38. Investigation of <math><mrow><msup><mi>K</mi><mo>+</mo></msup><msup><mi>K</mi><mo>−</mo></msup></mrow></math> interactions via femtoscopy in Pb-Pb collisions at <math><mrow><msqrt><msub><mi>s</mi><mrow><mi>N</mi><mi>N</mi></mrow></msub></msqrt><mo>=</mo><mn>2.76</mn></mrow></math> TeV at the CERN Large Hadron Collider

39. First measurement of the absorption of $^{3}\overline{\rm He}$ nuclei in matter and impact on their propagation in the galaxy

40. Inclusive quarkonium production in pp collisions at √s = 5.02 TeV

41. First measurement of $\Lambda_\mathrm{c}^{+}$ production down to $p_\mathrm{T} = 0$ in pp and p-Pb collisions at $\sqrt{s_\mathrm{NN}} = 5.02$ TeV

42. Light (anti)nuclei production in Pb-Pb collisions at $\sqrt{s_{\mathrm{NN}}}=5.02$ TeV

43. Two-particle transverse momentum correlations in pp and p-Pb collisions at LHC energies

44. CLL-106 First Prospective Data on Minimal Residual Disease Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-Line Treatment of CLL in Older Adult or Unfit Patients:The GLOW Study

45. Neutron emission in ultraperipheral Pb-Pb collisions at $\sqrt{s_{\mathrm{NN}}} = 5.02$ TeV

46. Comparative Characteristics of the Effectiveness of Tyrosine Kinase Inhibitors Vs Allogeneic Hematopoietic Stem Cell Transplantation in the Chronic Phase of Chronic Myeloid Leukemia

47. Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): The Glow Study

48. Poster: CML-395 Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update

49. Oral Abstract: CLL-106 First Prospective Data on Minimal Residual Disease Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-Line Treatment of CLL in Older Adult or Unfit Patients: The GLOW Study

50. Poster: MM-414 The Use of Non-Cryopreserved and Cryopreserved Hematopoietic Stem Cells for Autotransplantation in Multiple Myeloma

Catalog

Books, media, physical & digital resources